Alembic Pharmaceuticals Limited (APLLTD) reports strong Q2 FY27 performance with revenue up 36% and PAT up 81% YoY.
Alembic Pharmaceuticals Limited (APLLTD) secures USFDA final approval for Venetoclax Tablets, 10 mg, 50 mg, and 100 mg, expanding its generic drug portfolio.
Alembic Pharmaceuticals Limited (APLLTD) secures USFDA final approval for Valganciclovir for Oral Solution, expanding its generic drug portfolio.
Alembic Pharmaceuticals Limited (APLLTD) receives USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, expanding its generic drug po.
Alembic Pharmaceuticals Limited (APLLTD) reports a 26% YoY revenue surge in Q1 FY27, driven by strong growth in India Branded Business and US Formulation.
Alembic Pharmaceuticals Limited (APLLTD) secures USFDA final approval for Prucalopride Tablets, 1 mg and 2 mg, expanding its generic drug portfolio.
Alembic Pharmaceuticals Limited (APLLTD) announces USFDA final approval for Dapsone Gel, 5%, expanding its generic drug portfolio.
Alembic Pharmaceuticals Limited (APLLTD) announced USFDA final approval for Oseltamivir Phosphate Oral Suspension, 6 mg/mL, expanding its generic drug portfo.
Alembic Pharmaceuticals Limited (APLLTD) receives final approval from USFDA for Tretinoin Cream USP, 0.05%, with an estimated market size of US$ 76 million.
Alembic Pharmaceuticals Limited (APLLTD) secures USFDA tentative approval for Larotrectinib Capsules, marking a significant milestone.